Olufunmilayo Olopade to Ovarian Neoplasms
This is a "connection" page, showing publications Olufunmilayo Olopade has written about Ovarian Neoplasms.
Connection Strength
5.166
-
USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan. JAMA Netw Open. 2019 08 02; 2(8):e1910142.
Score: 0.425
-
Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015 Jan; 149(1):31-9.
Score: 0.307
-
Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat. 2010 Dec; 124(3):857-61.
Score: 0.228
-
Risk assessment and genetic testing for ovarian cancer. AJR Am J Roentgenol. 2010 Feb; 194(2):309-10.
Score: 0.220
-
Using genetic analysis to individualize preventive measures for breast and ovarian cancers. Nat Clin Pract Oncol. 2006 Apr; 3(4):182-3.
Score: 0.169
-
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33.
Score: 0.163
-
Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J. 2004 Jan-Feb; 10 Suppl 1:S5-9.
Score: 0.144
-
Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. Cancer Res Commun. 2023 11 28; 3(11):2420-2429.
Score: 0.143
-
Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. JAMA Oncol. 2023 11 01; 9(11):1547-1555.
Score: 0.143
-
FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell. 2003 May; 3(5):417-20.
Score: 0.138
-
Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiol Biomarkers Prev. 2022 07 01; 31(7):1351-1358.
Score: 0.130
-
Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022 03; 30(3):349-362.
Score: 0.126
-
Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiol Biomarkers Prev. 2021 11; 30(11):2038-2043.
Score: 0.122
-
Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2020 12; 159(3):820-826.
Score: 0.115
-
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020 10; 22(10):1653-1666.
Score: 0.113
-
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
Score: 0.105
-
A response to "Personalised medicine and population health: breast and ovarian cancer". Hum Genet. 2019 Mar; 138(3):287-289.
Score: 0.103
-
Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431.
Score: 0.102
-
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res. 2018 09 15; 78(18):5419-5430.
Score: 0.099
-
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 07 01; 109(7).
Score: 0.092
-
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691.
Score: 0.090
-
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266.
Score: 0.090
-
Genetics in clinical cancer care--the future is now. N Engl J Med. 1996 Nov 07; 335(19):1455-6.
Score: 0.088
-
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun. 2016 09 07; 7:12675.
Score: 0.087
-
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS One. 2016; 11(7):e0158801.
Score: 0.086
-
Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer. 2016 06 15; 122(12):1913-20.
Score: 0.084
-
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
Score: 0.082
-
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA Oncol. 2015 Jun; 1(3):306-13.
Score: 0.080
-
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2016 05; 141(2):386-401.
Score: 0.079
-
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
Score: 0.079
-
Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015 Feb; 47(2):164-71.
Score: 0.077
-
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):308-16.
Score: 0.076
-
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Nov; 148(2):397-406.
Score: 0.076
-
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 04; 10(4):e1004256.
Score: 0.073
-
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212.
Score: 0.068
-
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012 Aug; 21(8):1362-70.
Score: 0.065
-
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012 Apr 20; 30(12):1321-8.
Score: 0.064
-
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res. 2011 Sep 01; 71(17):5792-805.
Score: 0.061
-
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 01; 304(9):967-75.
Score: 0.057
-
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010 Nov; 124(1):195-203.
Score: 0.055
-
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res. 2009 Jul 15; 69(14):5801-10.
Score: 0.053
-
Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008 Mar; 10(3):161-166.
Score: 0.048
-
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006 Jul 12; 296(2):185-92.
Score: 0.043
-
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006 Mar; 7(3):223-9.
Score: 0.042
-
The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005 Jan; 96(1):222-6.
Score: 0.039
-
EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene. 2003 Aug 07; 22(32):5070-81.
Score: 0.035
-
The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cancer. 2023 03 15; 129(6):901-907.
Score: 0.034
-
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002 May 23; 346(21):1616-22.
Score: 0.032
-
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 2001 Oct; 11(7):635-8.
Score: 0.031
-
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020 03 01; 38(7):674-685.
Score: 0.027
-
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25.
Score: 0.025
-
Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples. J Med Genet. 2016 08; 53(8):548-58.
Score: 0.021
-
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002 Dec 04; 94(23):1773-9.
Score: 0.008
-
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002 Jun 05; 94(11):844-51.
Score: 0.008
-
Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000 Oct 01; 18(19):3360-9.
Score: 0.007
-
Evidence of a founder BRCA1 mutation in Scotland. Br J Cancer. 2000 Feb; 82(3):705-11.
Score: 0.007